Table 2.
Comparison of the clinical and epidemiological characteristics of the derivation and validation cohorts
|
Variables |
Total |
Derivationa |
Validationa |
p-valueb |
|---|---|---|---|---|
| N (%) | N (%) | |||
|
Country: |
|
|
|
0.002 |
| Spain |
2080 (67.6%) |
1048 (70.3%) |
1032 (65.1%) |
|
| Other |
995 (32.4%) |
442 (29.7%) |
553 (34.9%) |
|
|
Understanding: |
|
|
|
0.003 |
| Good |
2566 (91.7%) |
1266 (90.1%) |
1300 (93.3%) |
|
| Poor |
232 (8.29%) |
139 (9.89%) |
93 (6.68%) |
|
|
Living situation: |
|
|
|
0.250 |
| Alone |
312 (10.5%) |
157 (10.7%) |
155 (10.3%) |
|
| Homeless or institutionalized |
92 (3.10%) |
54 (3.69%) |
38 (2.52%) |
|
| Group |
376 (12.7%) |
189 (12.9%) |
187 (12.4%) |
|
| Family |
2191 (73.7%) |
1062 (72.6%) |
1129 (74.8%) |
|
|
Intravenous drug use: |
|
|
|
<0.001 |
| No |
1399 (45.5%) |
872 (58.5%) |
527 (33.2%) |
|
| Yes |
49 (1.59%) |
21 (1.41%) |
28 (1.77%) |
|
| Unknown |
1627 (52.9%) |
597 (40.1%) |
1030 (65.0%) |
|
|
Age (years): |
|
|
|
0.449 |
| 18-30 |
986 (32.3%) |
497 (33.4%) |
489 (31.3%) |
|
| 31-50 |
1233 (40.4%) |
596 (40.0%) |
637 (40.8%) |
|
| >50 |
834 (27.3%) |
397 (26.6%) |
437 (28.0%) |
|
|
Human immunodeficiency virus infection: |
|
|
|
<0.001 |
| No |
2284 (74.3%) |
1060 (71.1%) |
1224 (77.2%) |
|
| Yes |
148 (4.81%) |
66 (4.43%) |
82 (5.17%) |
|
| Unknown |
643 (20.9%) |
364 (24.4%) |
279 (17.6%) |
|
|
Use of directly observed treatment: |
|
0.017 |
|
|
| No |
2626 (91.1%) |
1338 (89.8%) |
1288 (92.4%) |
|
| Yes |
258 (8.95%) |
152 (10.2%) |
106 (7.60%) |
|
|
Sex: |
|
|
|
0.476 |
| Male |
1945 (64.0%) |
920 (63.4%) |
1025 (64.7%) |
|
| Female |
1092 (36.0%) |
532 (36.6%) |
560 (35.3%) |
|
|
Country- Healthcare |
|
|
|
<0.001 |
| Primary care |
511 (17.1%) |
268 (18.0%) |
243 (16.1%) |
|
| Urgent care |
1461 (48.8%) |
682 (45.8%) |
779 (51.7%) |
|
| Specialist |
476 (15.9%) |
210 (14.1%) |
266 (17.7%) |
|
| Unknown' |
548 (18.3%) |
330 (22.1%) |
218 (14.5%) |
|
|
Employment: |
|
|
|
<0.001 |
| Disabled |
98 (3.39%) |
68 (4.70%) |
30 (2.08%) |
|
| Employed |
1781 (61.6%) |
901 (62.3%) |
880 (60.9%) |
|
| Unemployed |
547 (18.9%) |
257 (17.8%) |
290 (20.1%) |
|
| Retired |
464 (16.1%) |
220 (15.2%) |
244 (16.9%) |
|
|
Previous anti-tuberculosis treatment: |
|
|
|
0.304 |
| No |
2728 (91.5%) |
1320 (91.0%) |
1408 (92.1%) |
|
| Yes |
252 (8.46%) |
131 (9.03%) |
121 (7.91%) |
|
|
Lost to follow-up outcome |
|
|
|
0.974 |
| No |
2814 (93.5%) |
1332 (93.5%) |
1482 (93.5%) |
|
| Yes | 195 (6.48%) | 92 (6.46%) | 103 (6.50%) |
aData from the derivation group was used to create the model and data from the validation group was used to valídate the model.
bp values according to χ2 test with correction for continuity.